Perioperative Management & Cancer Recurrence: Why Clinical Trials Fall Short

For over a decade, medical researchers have investigated how surgical procedures and perioperative care impact long-term outcomes for cancer patients. Despite promising results from laboratory studies suggesting that surgical invasiveness and medication choices during and after surgery could influence cancer recurrence, translating these findings into consistent clinical improvements has proven elusive.

This challenge is particularly acute in thoracic surgery, where significant advancements have recently been made in lung cancer treatment. These include the adoption of minimally invasive techniques – such as video-assisted, robotic, uniportal and monoportal approaches – alongside improved post-surgical rehabilitation programs and multimodal treatment strategies incorporating neoadjuvant immunotherapy.

Recent research highlights the increasing prevalence of lung cancer as the primary reason for major thoracic surgery, even among patients who have undergone lung transplantation. Oncological intended thoracic surgery is considered a viable option following transplantation, but carries a demonstrably higher risk of postoperative complications, according to a study published in the Journal of Thoracic and Cardiovascular Surgery.

The pursuit of improved outcomes extends beyond surgical technique. Experts emphasize the importance of balancing effective cancer removal with the preservation of organ functionality, a critical consideration particularly in early-stage lung cancer cases. The emergence of robotic-assisted surgery exemplifies this trend, offering a potentially less invasive approach to complex procedures.

The focus on perioperative management reflects a broader effort to understand the systemic effects of surgery on cancer progression. While preclinical studies have identified potential mechanisms linking surgical stress and immune response to tumor recurrence, robust clinical trials are needed to validate these findings and establish evidence-based guidelines for optimizing patient care. The Department of Thoracic Surgery and the Department of Oncology are both involved in treating lung cancer patients, with the latter often providing adjuvant chemotherapy or systemic therapy following surgical intervention.

Currently, the oncological effect of perioperative management remains an area of active investigation, with no definitive clinical trials yet demonstrating a clear pathway to reducing recurrence rates.